BEAM (Beam Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BEAM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-29 | Amy Simon | Chief Medical Officer | Sell | — | — |
| 2026-07-02 | Amy Simon | Chief Medical Officer | Sell | — | — |
| 2026-07-01 | John M. Evans | CEO | MIXED | — | — |
| 2026-06-29 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2026-06-22 | Giuseppe Ciaramella | President | M | — | — |
| 2026-06-05 | GRAHAM K COOPER | Director | A | — | — |
| 2026-06-05 | JOHN MARAGANORE | Director | A | — | — |
| 2026-06-05 | Christi Shaw | Director | A | — | — |
| 2026-06-05 | Mark Fishman | Director | A | — | — |
| 2026-06-05 | Kathleen E Walsh | Director | A | — | — |
| 2026-06-05 | Chirfi Guindo | Director | A | — | — |
| 2026-04-06 | Christine Bellon | Chief Legal Officer | Sell | — | — |
| 2026-04-06 | Amy Simon | Chief Medical Officer | Sell | — | — |
| 2026-04-06 | John M. Evans | CEO | Sell | — | — |
| 2026-04-06 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | — | — |
| 2026-04-06 | Giuseppe Ciaramella | President | Sell | — | — |
| 2026-04-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | A | — | — |
| 2026-04-02 | Christine Bellon | Chief Legal Officer | A | — | — |
| 2026-04-02 | Sravan Kumar Emany | Chief Financial Officer | A | — | — |
| 2026-04-02 | Giuseppe Ciaramella | President | A | — | — |
| 2026-04-02 | Amy Simon | Chief Medical Officer | A | — | — |
| 2026-04-01 | John M. Evans | CEO | MIXED | — | — |
| 2026-02-26 | Giuseppe Ciaramella | President | MIXED | — | — |
| 2026-02-02 | Sravan Kumar Emany | Chief Financial Officer | A | — | — |
| 2026-02-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | A | — | — |
| 2026-02-02 | Christine Bellon | Chief Legal Officer | A | — | — |
| 2026-02-02 | Giuseppe Ciaramella | President | A | — | — |
| 2026-02-02 | John M. Evans | CEO | MIXED | — | — |
| 2026-02-02 | Amy Simon | Chief Medical Officer | A | — | — |
| 2026-01-26 | Christine Bellon | Chief Legal Officer | Sell | — | — |
| 2026-01-26 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | — | — |
| 2026-01-21 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | — | — |
| 2026-01-20 | Christine Bellon | Chief Legal Officer | Sell | — | — |
| 2026-01-05 | Sravan Kumar Emany | Chief Financial Officer | Sell | — | — |
| 2026-01-05 | Amy Simon | Chief Medical Officer | A | — | — |
| 2026-01-05 | Christine Bellon | Chief Legal Officer | Sell | — | — |
| 2025-10-29 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-10-08 | FMR LLC | 10%+ Owner | G | — | — |
| 2025-10-03 | Christine Bellon | Chief Legal Officer | Sell | — | — |
| 2025-10-03 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | — | — |
| 2025-10-03 | John M. Evans | CEO | MIXED | — | — |
| 2025-08-01 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-07-03 | Amy Simon | Chief Medical Officer | Sell | — | — |
| 2025-06-06 | JOHN MARAGANORE | Director | A | — | — |
| 2025-06-06 | Mark Fishman | Director | A | — | — |
| 2025-06-06 | Carole Ho | Director | A | — | — |
| 2025-06-06 | GRAHAM K COOPER | Director | A | — | — |
| 2025-06-06 | Kathleen E Walsh | Director | A | — | — |
| 2025-06-06 | Christi Shaw | Director | A | — | — |
| 2025-06-06 | Chirfi Guindo | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,535,572 | — |
| — | 10%+ Owner | 3,523,953 | — |
| — | 10%+ Owner | 3,331,737 | — |
| — | 10%+ Owner | 2,949,630 | — |
| — | Director | 2,747,530 | — |
| — | CEO | 1,175,205 | — |
| — | 10%+ Owner | 1,161,458 | — |
| — | 10%+ Owner | 1,106,071 | — |
| — | President | 253,911 | — |
| — | Chief Legal Officer | 109,711 | — |
| — | Chief Financial Officer | 105,456 | — |
| — | Chief Medical Officer | 85,696 | — |
| — | Chief Financial Officer | 82,637 | — |
| — | SVP, Finance and Treasurer | 51,171 | — |
| — | Director | 17,007 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BEAM quote page; the site-wide leaderboard is on the insider transactions hub.